IFG Advisory’s CytomX Therapeutics CTMX Stock Holding History

IFG Advisory’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$569K	Buy	+209,243	New	+$698K	0.02%	578

Other funds holding CTMX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Peak Financial Advisors Denver, Colorado $232M AUM 12.16% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

IFG Advisory's CTMX Position: Q3 2026 in Review

IFG Advisory opened a new position in CytomX Therapeutics (CTMX) in Q3 2026: 209,243 shares worth $569K. The stake represents 0.02% of the portfolio and ranks #578 among its holdings.

50 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

IFG Advisory held 209,243 shares of CytomX Therapeutics worth $569K as of Q3 2026.
CytomX Therapeutics was a new IFG Advisory position in Q3 2026.
CytomX Therapeutics made up 0.02% of IFG Advisory's portfolio in Q3 2026, its #578 holding.
50 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on IFG Advisory's 13F filing for Q3 2026, filed 9 Nov 2026.